ライフサイエンスコーパス: 4-phenylbutyrate

1 us administration of the molecular chaperone 4-phenylbutyrate.

2 sobutyl-1-methylxanthine, 2) BPDZ 154, or 3) 4-phenylbutyrate.

3 ydroxy-4-phenylbutyrate, and 2-hydroxy-4-oxo-4-phenylbutyrate.

4 In vitro, chaperone drugs, such as 4-phenylbutyrate (4-PB), have been shown to partially co

5 tive effect of the chemical chaperone sodium 4-phenylbutyrate (4-PBA) on mutant UMOD maturation.

6 previously shown that the chemical chaperone 4-phenylbutyrate (4-PBA) promotes the maturation of ABCC

7 The therapeutic peroxisome proliferator, 4-phenylbutyrate (4-PBA) was investigated in vitro and i

8 Treatment of mice with 4-phenylbutyrate (4-PBA), a chemical chaperon and a pote

9 between SURF4 and SEC24A can be inhibited by 4-phenylbutyrate (4-PBA), a small molecule that occludes

10 chaperones tauroursodeoxycholate (TUDCA) and 4-phenylbutyrate (4-PBA), as well as the iron chelator c

11 ion process using the proteostasis regulator 4-phenylbutyrate (4-PBA), which we show targets COPII pr

12 ization for rescue by the chemical chaperone 4-phenylbutyrate (4-PBA).

13 ine (NAC, a blocker of oxidative stress) and 4-phenylbutyrate (4-PBA, a blocker of endoplasmic reticu

14 n and chaperone drugs (ursodeoxycholic acid, 4-phenylbutyrate [4-PB]) were investigated.

15 hen cellular coupling was strengthened using 4-phenylbutyrate (4PB).

16 Previous studies have shown that both 4-phenylbutyrate (4PBA) and trichostatin A (TSA) increas

17 ules include histone deacetylase inhibitors, 4-phenylbutyrate (4PBA) and trichostatin A, and two smal

18 Sodium 4-phenylbutyrate (4PBA) corrects trafficking of DeltaF50

19 Sodium 4-phenylbutyrate (4PBA) improves the intracellular traff

20 T mutation with a chemical chaperone, sodium 4-phenylbutyrate (4PBA), reduces ER stress/UPR and impro

21 A chemical corrector, 4-phenylbutyrate (4PBA), restored LGI1(E383A) folding an

22 at a known transcriptional regulator, sodium 4-phenylbutyrate (4PBA), will enable a greater fraction

23 Treating Col4a1(+/G1344D) mice with 4-phenylbutyrate, a compound that promotes the trafficki

24 ter treatment of PBD fibroblasts with sodium 4-phenylbutyrate, a human peroxisome proliferator, there

25 Encouragingly, however, 4-phenylbutyrate, a pharmacological corrector, reduced L

26 Encouragingly, however, 4-phenylbutyrate, a pharmacological corrector, reduced L

27 t that a low temperature eye mask and sodium 4-phenylbutyrate, a United States Food and Drug Administ

28 Supporting this, treatment with 4-phenylbutyrate, a well-known chemical chaperone that i

29 mbinations of protein repair agents, such as 4-phenylbutyrate and genistein, may be necessary to rest

30 Sodium 4-phenylbutyrate and glycerol displayed a significant sy

31 In contrast, sodium 4-phenylbutyrate and probenecid, the latter a uricosuric

32 The chemical chaperones sodium 4-phenylbutyrate and tauroursodeoxycholic acid were foun

33 ess using small chemical chaperones, such as 4-phenylbutyrate and tauroursodeoxycholic acid, also att

34 of two different chemical chaperones, sodium 4-phenylbutyrate and tauroursodeoxycholic acid, both wit

35 tion were mimicked by HDAC inhibitors sodium 4-phenylbutyrate and trichostatin A (TSA).

36 yrate, 3-(4-hydroxyphenyl)lactate, 2-hydroxy-4-phenylbutyrate, and 2-hydroxy-4-oxo-4-phenylbutyrate.

37 The ER stress inhibitor, 4-phenylbutyrate, blocked CITED2 knockdown-induced apopt

38 Importantly, we found that sodium 4-phenylbutyrate (Buphenyl(R)), a drug used to treat ure

39 Sodium 4-phenylbutyrate (Buphenyl, 4PBA) is a new FDA approved

40 Furthermore, we show that 4-phenylbutyrate can rescue the enamel phenotype in affe

41 ose cells with the chemical chaperone sodium 4-phenylbutyrate could partially restore trafficking of

42 Treatment with the peroxisome proliferator 4-phenylbutyrate exerted protective effects with improve

43 Inactivation of client cargo sorting using 4-phenylbutyrate had opposing reciprocal effects on clie

44 e of VCP, MLN-273 (proteasome inhibitor), or 4-phenylbutyrate (histone deacetylase inhibitor).

45 The chemical chaperon, 4-phenylbutyrate, increased the mutant solubility, reduc

46 l, and the transcriptional regulator, sodium 4-phenylbutyrate, inhibit the constitutively activated i

47 hat induce peroxisome proliferation, such as 4-phenylbutyrate, may have therapeutic potential in the

48 Further, lowering ER stress by 4-phenylbutyrate mitigated the enhanced immune stimulati

49 ed that administration of chemical chaperone 4-phenylbutyrate or genetic inhibition of ATF4 successfu

50 feeding Drosophila throughout adulthood with 4-phenylbutyrate (PBA) can significantly increase lifesp

51 known to suppress ER stress signaling, like 4-phenylbutyrate (PBA) or tauroursodeoxycholic acid, wil

52 s to determine whether topical ocular sodium 4-phenylbutyrate (PBA) treatment rescues glaucoma phenot

53 Systemic administration of sodium 4-phenylbutyrate (PBA), a chemical chaperone, increased

54 ent with chemical chaperones, such as sodium 4-phenylbutyrate (PBA), reduces protein aggregation in n

55 chaperones tauroursodeoxycholate (TUDCA) and 4-phenylbutyrate (PBA), which facilitate protein folding

56 reduction of ER stress in the TM with sodium 4-phenylbutyrate prevented dexamethasone-induced ocular

57 In addition, glycerol and sodium 4-phenylbutyrate reduced the amount of Hsc70 expressed i

58 inically approved chemical chaperone, sodium 4-phenylbutyrate reduced the platelet hyperactivation.

59 Treatment with 4-phenylbutyrate resulted in remarkable amelioration of

60 Colchicine and sodium 4-phenylbutyrate reverse these processes and could poten

61 uced UPR/ER stress by the chemical chaperone 4-phenylbutyrate significantly alleviated astrocyte-medi

62 ndent on IRE1b and to be inhibited by sodium 4-phenylbutyrate, suggesting that heat-induced autophagy

63 Colchicine and sodium 4-phenylbutyrate treatment increased secretion of THP fr

64 We show that 4-phenylbutyrate treatment of cells from both X-ALD pati

65 demonstrate the in vivo efficacy of dietary 4-phenylbutyrate treatment through its production of a s

66 After 4-phenylbutyrate treatment, an increase in transcription

67 ked by treatment with the chemical chaperone 4-phenylbutyrate, uncovering the involvement of ER stres

68 chaperones (thapsigargin, glycerol or sodium 4-phenylbutyrate), we demonstrated a marked increase in